Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1999 1
2002 4
2003 12
2004 31
2005 42
2006 78
2007 114
2008 173
2009 170
2010 216
2011 280
2012 341
2013 385
2014 437
2015 472
2016 483
2017 487
2018 566
2019 549
2020 442
2021 417
2022 366
2023 318
2024 138

Text availability

Article attribute

Article type

Publication date

Search Results

5,788 results

Results by year

Filters applied: . Clear all
Page 1
Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates.
Brown CR, Gupta S, Qin J, Racie T, He G, Lentini S, Malone R, Yu M, Matsuda S, Shulga-Morskaya S, Nair AV, Theile CS, Schmidt K, Shahraz A, Goel V, Parmar RG, Zlatev I, Schlegel MK, Nair JK, Jayaraman M, Manoharan M, Brown D, Maier MA, Jadhav V. Brown CR, et al. Nucleic Acids Res. 2020 Dec 2;48(21):11827-11844. doi: 10.1093/nar/gkaa670. Nucleic Acids Res. 2020. PMID: 32808038 Free PMC article.
One hallmark of trivalent N-acetylgalactosamine (GalNAc)-conjugated siRNAs is the remarkable durability of silencing that can persist for months in preclinical species and humans. ...Identical siRNAs delivered in lipid nanoparticles or as GalNAc conjugates were dose …
One hallmark of trivalent N-acetylgalactosamine (GalNAc)-conjugated siRNAs is the remarkable durability of silencing that can persist …
RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies.
Traber GM, Yu AM. Traber GM, et al. J Pharmacol Exp Ther. 2023 Jan;384(1):133-154. doi: 10.1124/jpet.122.001234. Epub 2022 Jun 9. J Pharmacol Exp Ther. 2023. PMID: 35680378 Free PMC article. Review.
The major forms of RNAi molecules, genome-derived microRNAs (miRNAs) and exogenous small interfering RNAs (siRNAs), converge into RNA-induced silencing complexes to achieve posttranscriptional gene regulation. ...We overview the pharmacology of the fou …
The major forms of RNAi molecules, genome-derived microRNAs (miRNAs) and exogenous small interfering RNAs (siRNAs), con …
Copackaging photosensitizer and PD-L1 siRNA in a nucleic acid nanogel for synergistic cancer photoimmunotherapy.
Guo Y, Zhang Q, Zhu Q, Gao J, Zhu X, Yu H, Li Y, Zhang C. Guo Y, et al. Sci Adv. 2022 Apr 22;8(16):eabn2941. doi: 10.1126/sciadv.abn2941. Epub 2022 Apr 20. Sci Adv. 2022. PMID: 35442728 Free PMC article.
Packaging multiple drugs into a nanocarrier with rational design to achieve synergistic cancer therapy remains a challenge due to the intrinsically varied pharmacodynamics of therapeutic agents. Especially difficult is combining small-molecule drugs and macromolecular biol …
Packaging multiple drugs into a nanocarrier with rational design to achieve synergistic cancer therapy remains a challenge due to the intrin …
The landscape of nanoparticle-based siRNA delivery and therapeutic development.
Moazzam M, Zhang M, Hussain A, Yu X, Huang J, Huang Y. Moazzam M, et al. Mol Ther. 2024 Feb 7;32(2):284-312. doi: 10.1016/j.ymthe.2024.01.005. Epub 2024 Jan 10. Mol Ther. 2024. PMID: 38204162 Review.
Five small interfering RNA (siRNA)-based therapeutics have been approved by the Food and Drug Administration (FDA), namely patisiran, givosiran, lumasiran, inclisiran, and vutrisiran. ...For this purpose, several modifications have been employed to …
Five small interfering RNA (siRNA)-based therapeutics have been approved by the Food and Drug Administration (FD …
Plant Noncoding RNAs: Hidden Players in Development and Stress Responses.
Yu Y, Zhang Y, Chen X, Chen Y. Yu Y, et al. Annu Rev Cell Dev Biol. 2019 Oct 6;35:407-431. doi: 10.1146/annurev-cellbio-100818-125218. Epub 2019 Aug 12. Annu Rev Cell Dev Biol. 2019. PMID: 31403819 Free PMC article. Review.
In this review, we summarize the current knowledge of plant small RNAs and lncRNAs, with a focus on their biogenesis, modes of action, local and systemic movement, and functions at the nexus of plant development and environmental responses. The complex connections among …
In this review, we summarize the current knowledge of plant small RNAs and lncRNAs, with a focus on their biogenesis, modes of action …
In vivo self-assembled small RNAs as a new generation of RNAi therapeutics.
Fu Z, Zhang X, Zhou X, Ur-Rehman U, Yu M, Liang H, Guo H, Guo X, Kong Y, Su Y, Ye Y, Hu X, Cheng W, Wu J, Wang Y, Gu Y, Lu SF, Wu D, Zen K, Li J, Yan C, Zhang CY, Chen X. Fu Z, et al. Cell Res. 2021 Jun;31(6):631-648. doi: 10.1038/s41422-021-00491-z. Epub 2021 Mar 29. Cell Res. 2021. PMID: 33782530 Free PMC article.
RNAi therapy has undergone two stages of development, direct injection of synthetic siRNAs and delivery with artificial vehicles or conjugated ligands; both have not solved the problem of efficient in vivo siRNA delivery. Here, we present a proof-of-principle strate …
RNAi therapy has undergone two stages of development, direct injection of synthetic siRNAs and delivery with artificial vehicles or c …
Ginsenoside Rb1 inhibits oxidative stress-induced ovarian granulosa cell injury through Akt-FoxO1 interaction.
Zhou P, Deng F, Yang Z, Cao C, Zhao H, Liu F, Zhong K, Fu L, Peng T, Sun D, Liu H, Li R, Yu Y. Zhou P, et al. Sci China Life Sci. 2022 Nov;65(11):2301-2315. doi: 10.1007/s11427-021-2080-x. Epub 2022 Jun 1. Sci China Life Sci. 2022. PMID: 35661967
The protective effects of Rb1 were investigated and the role of Rb1 on the modulation of Akt-FoxO1 interaction was determined with immunofluorescence, Western blotting, immunoprecipitation, siRNA silencing and pharmacological inhibitor. Rb1 effectively decreased LDH and MD …
The protective effects of Rb1 were investigated and the role of Rb1 on the modulation of Akt-FoxO1 interaction was determined with immunoflu …
MBD2 facilitates tumor metastasis by mitigating DDB2 expression.
Zhang L, Wang S, Wu GR, Yue H, Dong R, Zhang S, Yu Q, Yang P, Zhao J, Zhang H, Yu J, Yuan X, Xiong W, Yang X, Yong T, Wang CY. Zhang L, et al. Cell Death Dis. 2023 May 4;14(5):303. doi: 10.1038/s41419-023-05804-1. Cell Death Dis. 2023. PMID: 37142578 Free PMC article.
Mechanistically, MBD2 selectively bound to the methylated CpG DNA within the DDB2 promoter, by which MBD2 repressed DDB2 expression to promote tumor metastasis. As a result, administration of MBD2 siRNA-loaded liposomes remarkably suppressed EMT along with attenuated tumor …
Mechanistically, MBD2 selectively bound to the methylated CpG DNA within the DDB2 promoter, by which MBD2 repressed DDB2 expression to promo …
siRNA-based approaches for castration-resistant prostate cancer therapy targeting the androgen receptor signaling pathway.
Yu Y, Papukashvili D, Ren R, Rcheulishvili N, Feng S, Bai W, Zhang H, Xi Y, Lu X, Xing N. Yu Y, et al. Future Oncol. 2023 Sep;19(30):2055-2073. doi: 10.2217/fon-2023-0227. Epub 2023 Oct 12. Future Oncol. 2023. PMID: 37823367 Review.
Thus there is a critical need for more specific medication to treat CRPC. Small interfering RNAs have shown great potential as a targeted therapy. This review discusses prostate cancer progression and the role of AR signaling in CRPC, and proposes siRNA-based …
Thus there is a critical need for more specific medication to treat CRPC. Small interfering RNAs have shown great potential as …
siRNA Delivery to Melanoma Cells with Cationic Niosomes.
Obeid MA, Alyamani H, Amawi H, Aljabali AAA, Rezigue M, Abdeljaber SN, Ferro VA. Obeid MA, et al. Methods Mol Biol. 2021;2265:621-634. doi: 10.1007/978-1-0716-1205-7_42. Methods Mol Biol. 2021. PMID: 33704743
RNA interference (RNAi) is a posttranscriptional regulatory mechanism that employs siRNA. ...Here we describe the transfection of melanoma cancer cells with siRNA using cationic niosome nanoparticles as a delivery system. ...
RNA interference (RNAi) is a posttranscriptional regulatory mechanism that employs siRNA. ...Here we describe the transfection …
5,788 results